Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) - Total Liabilities

Latest as of September 2025: CN¥142.19 Million CNY ≈ $20.81 Million USD

Based on the latest financial reports, Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) has total liabilities worth CN¥142.19 Million CNY (≈ $20.81 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 301211 cash generation efficiency to assess how effectively this company generates cash.

Hubei Biocause Heilen Pharmaceutical Co. Ltd. - Total Liabilities Trend (2017–2024)

This chart illustrates how Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Hubei Biocause Heilen Pharmaceutical Co. to evaluate the company's liquid asset resilience ratio.

Hubei Biocause Heilen Pharmaceutical Co. Ltd. Competitors by Total Liabilities

The table below lists competitors of Hubei Biocause Heilen Pharmaceutical Co. Ltd. ranked by their total liabilities.

Company	Country	Total Liabilities
W olf Photoelectric Technology Ltd SHE:002962	China	CN¥392.65 Million
Braskem S.A. SA:BRKM3	Brazil	R$90.56 Billion
Hippo Holdings Inc NYSE:HIPO	USA	$1.45 Billion
Thinking Electronic Industrial Co Ltd TW:2428	Taiwan	NT$5.07 Billion
Lg Electronics Pref KO:066575	Korea	₩40.25 Trillion
Kronos Worldwide Inc NYSE:KRO	USA	$1.10 Billion
Tatwah Smartech Co Ltd SHE:002512	China	CN¥2.01 Billion
AFYA LTD. CL.A DL-00005 F:1AY	Germany	€4.47 Billion

Liability Composition Analysis (2017–2024)

This chart breaks down Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 301211 market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	13.95	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.06	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.06	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Hubei Biocause Heilen Pharmaceutical Co. Ltd. (2017–2024)

The table below shows the annual total liabilities of Hubei Biocause Heilen Pharmaceutical Co. Ltd. from 2017 to 2024.

Year	Total Liabilities	Change
2024-12-31	CN¥178.97 Million ≈ $26.19 Million	-5.75%
2023-12-31	CN¥189.89 Million ≈ $27.79 Million	-14.16%
2022-12-31	CN¥221.22 Million ≈ $32.37 Million	+105.73%
2021-12-31	CN¥107.53 Million ≈ $15.73 Million	+4.55%
2020-12-31	CN¥102.85 Million ≈ $15.05 Million	-60.03%
2019-12-31	CN¥257.31 Million ≈ $37.65 Million	+7.05%
2018-12-31	CN¥240.36 Million ≈ $35.17 Million	+5.77%
2017-12-31	CN¥227.25 Million ≈ $33.25 Million	--

About Hubei Biocause Heilen Pharmaceutical Co. Ltd.

SHE:301211 China Drug Manufacturers - Specialty & Generic

Market Cap

$702.13 Million

CN¥4.80 Billion CNY

Market Cap Rank

#10837 Global

#3195 in China

Share Price

CN¥11.49

Change (1 day)

+0.35%

52-Week Range

CN¥11.04 - CN¥20.13

All Time High

CN¥44.40